Bio-Techne Corporation (TECH)
After hours:
| Previous close | 72.37 |
| Open | 72.37 |
| Bid | 71.45 x 100 |
| Ask | 71.72 x 100 |
| Day's range | 70.83 - 73.98 |
| 52-week range | 51.79 - 85.57 |
| Volume | |
| Avg. volume | 977,133 |
| Market cap | 11.338B |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | 68.09 |
| EPS (TTM) | 1.05 |
| Earnings date | 29 Oct 2024 - 04 Nov 2024 |
| Forward dividend & yield | 0.32 (0.45%) |
| Ex-dividend date | 19 Aug 2024 |
| 1y target est | 82.78 |
Simply Wall St.Some May Be Optimistic About Bio-Techne's (NASDAQ:TECH) Earnings
Soft earnings didn't appear to concern Bio-Techne Corporation's ( NASDAQ:TECH ) shareholders over the last week. Our...
PR NewswireScaleReady announces the inaugural G-Rex® Grant has been awarded to Stanford Medicine Laboratory for Cell and Gene Medicine
ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine's Laboratory for Cell and Gene Medicine (LCGM), has been awarded the inaugural G-Rex® Grant. Dr. Feldman's $300,000 G-Rex Grant will enable expeditious development of Stanford Medicine's LCGM's G-Rex platform for CAR-T cell therapy manufacturing, which will be offered to internal investig
- PR Newswire
BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES
Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor conferences:
